c-Met Monoclonal Antibody (3D4) | Invitrogen 37-0100 product information

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

c-Met Monoclonal Antibody (3D4)

catalog :

37-0100

quantity :

100µg

price :

US 309.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

3D4

reactivity :

human, mouse

application :

western blot, ELISA, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section, immunohistochemistry - frozen section, western blot knockout validation

more info or order :

Invitrogen product webpage

citations: 16

Published Application/Species/Sample/Dilution	Reference
western blot knockout validation; mouse; fig s1 ELISA; mouse	Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson A, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522:349-53 pubmed publisher
flow cytometry; human; tbl 2 immunocytochemistry; human	Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler J, et al. Development of a Novel c-MET-Based CTC Detection Platform. Mol Cancer Res. 2016;14:539-47 pubmed publisher
western blot; human; 1:1000; loading ...; fig st3	Nassour J, Martien S, Martin N, Deruy E, Tomellini E, Malaquin N, et al. Defective DNA single-strand break repair is responsible for senescence and neoplastic escape of epithelial cells. Nat Commun. 2016;7:10399 pubmed publisher
western blot; human; fig s1	Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, et al. H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget. 2015;6:29209-23 pubmed publisher
immunohistochemistry - paraffin section; human; 1:200	Kim Y, Jin D, Lee B, Cho E, Han J, Shim Y, et al. RARÎ²2 hypermethylation is associated with poor recurrence-free survival in never-smokers with adenocarcinoma of the lung. Clin Epigenetics. 2015;7:32 pubmed publisher
western blot; human; fig 2	Mahadevan D, Theiss N, Morales C, Stejskal A, Cooke L, Zhu M, et al. Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST). Oncotarget. 2015;6:1954-66 pubmed
immunocytochemistry; human; 1:100	Xie Y, Lu W, Liu S, Yang Q, Carver B, Li E, et al. Crosstalk between nuclear MET and SOX9/?-catenin correlates with castration-resistant prostate cancer. Mol Endocrinol. 2014;28:1629-39 pubmed publisher
western blot; human	Martin V, Corso S, Comoglio P, Giordano S. Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence. Mol Oncol. 2014;8:1561-74 pubmed publisher
immunohistochemistry - frozen section; human; 1:50; fig 4 western blot; human; 1:250; fig 2	Lee S, Seol H, Lee H, Kang W, Kang B, Jin J, et al. Gene silencing of c-Met leads to brain metastasis inhibitory effects. Clin Exp Metastasis. 2013;30:845-54 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50	Jung Y, Joo K, Seong D, Choi Y, Kong D, Kim Y, et al. Identification of prognostic biomarkers for glioblastomas using protein expression profiling. Int J Oncol. 2012;40:1122-32 pubmed publisher
western blot; human; fig 3	Seiwert T, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69:3021-31 pubmed publisher
immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 2a	Kong D, Song S, Kim D, Joo K, Yoo J, Koh J, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140-8 pubmed publisher
	Schmitz K, Koeppen H, Binot E, Fassunke J, KÃ¼nstlinger H, Ihle M, et al. MET gene copy number alterations and expression of MET and hepatocyte growth factor are potential biomarkers in angiosarcomas and undifferentiated pleomorphic sarcomas. PLoS ONE. 2015;10:e0120079 pubmed publisher
	Tuynman J, Lagarde S, ten Kate F, Richel D, van Lanschot J. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer. 2008;98:1102-8 pubmed publisher
	Tolgay Ocal I, Dolled Filhart M, D Aquila T, Camp R, Rimm D. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer. 2003;97:1841-8 pubmed
	Kang J, Dolled Filhart M, Ocal I, Singh B, Lin C, Dickson R, et al. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 2003;63:1101-5 pubmed

product information

Product Type :

Antibody

Product Name :

c-Met Monoclonal Antibody (3D4)

Catalog # :

37-0100

Quantity :

100µg

Price :

US 309.00

Clonality :

Monoclonal

Purity :

Affinity chromatography

Host :

Mouse

Reactivity :

Human

Applications :

ELISA: 0.1-1 µg/mL, Immunohistochemistry: 5-10 µg/mL, Immunoprecipitation: Assay Dependent, Western Blot: 1-3 µg/mL

Species :

Human

Clone :

3D4

Isotype :

IgG2a

Storage :

-20°C

Description :

The c-Met oncogene was originally isolated from a chemical carcinogen-treated human osteogenic sarcoma cell line by transfection analysis in NIH/3T3 cells. The Met proto-oncogene product was identified as a transmembrane receptor-like protein with tyrosine kinase activity that is expressed in many tissues. The c-Met gene product has been identified as the cell surface receptor for hepatocyte growth factor, a plasminogen-like protein thought to be a humoral mediator of liver regeneration. c-Met, also known as HGF receptor or SF receptor, is activated by hepatocyte growth factor (HGF) or scatter factor (SF), and is composed of alpha and beta subunits linked by disulfide bonds. The alpha subunit of c-Met is extracellular and heavily glycosylated; the beta subunit contains an extracellular portion involved in ligand binding, a transmembrane segment, and a cytoplasmic tyrosine kinase domain. The truncated cytoplasmic region of c-Met has constitutive kinase activity and is oncogenic, but requires the first 39 amino acids of the juxtamembrane domain and the regulatory tyrosine in the catalytic domain to enact its transforming potential.

Immunogen :

Synthetic peptide derived from cytoplasmic domain of human c-Met protein.

Format :

Liquid

Applications w/Dilutions :

ELISA: 0.1-1 µg/mL, Immunohistochemistry: 5-10 µg/mL, Immunoprecipitation: Assay Dependent, Western Blot: 1-3 µg/mL

Aliases :

EC 2.7.10.1, HGF receptor, HGF-SF receptor, Hepatocyte growth factor receptor precursor, Met proto- oncogene tyrosine kinase, c-met, kinase EC 2.7.10.1, HGF receptor, HGF-SF receptor, Hepatocyte growth factor receptor precursor, Met proto- oncogene tyros

more info or order :

Invitrogen product webpage